Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Cyanocobalamin 50 micrograms Film-coated Tablets

Active Ingredient:
cyanocobalamin
Company:  
Glenmark Pharmaceuticals Europe Ltd See contact details
ATC code: 
B03BA01
{info_black}
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 27 Oct 2023
1. Name of the medicinal product

Cyanocobalamin 50 micrograms Film-coated Tablets

2. Qualitative and quantitative composition

Each tablet contains 50 micrograms Cyanocobalamin.

Excipient(s) with known effect: Contains 116.955 mg of lactose monohydrate.

For the full list of excipients, see section 6.1

Cyanocobalamin contains cobalt.

3. Pharmaceutical form

Film-coated Tablet (Tablet).

Pink coloured round biconvex film-coated tablets (diameter about 7.00 mm) debossed with '45' on one side and 'G' on other side.

4. Clinical particulars
4.1 Therapeutic indications

Cyanocobalamin is indicated for:

- Treatment of nutritional vitamin B12 deficiency

- Treatment of vitamin B12 deficiency following partial gastrectomy

- Treatment of tropical sprue, alone or with folic acid

- Treatment of pernicious anaemia when parenteral administration is not possible or not advised.

4.2 Posology and method of administration

Posology

Adults: one to three tablets (50 to 150 micrograms) or more daily at the discretion of the physician.

In pernicious anaemia intramuscular therapy is preferable for initial correction of vitamin B12 deficiency. However, if necessary, the oral route may be used to follow this, in which case at least 300 micrograms should be given daily.

Elderly: The normal dose for adults is appropriate for the elderly.

Paediatric population: One tablet (50 micrograms) daily at the discretion of the physician.

Method of administration: Oral.

This medicine should be taken between meals.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

For pernicious anaemia, an adequate dose must be used and the blood picture must be examined regularly at least every three months for 18 months until stabilised, and then annually.

Indiscriminate administration of this medicine may mask precise diagnosis.

Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Absorption may be reduced by Para-aminosalicylic acid, colchinine, biguanides, neomycin, cholestyramine, potassium chloride, methyldopa, and cimetidine.

Patients treated with chloramphenicol may respond poorly to this medicine.

Serum levels of this medicine may be lowered by oral contraceptives. These interactions are unlikely to have clinical significance.

Anti-metabolities and most antibiotics invalidate vitamins B12 assays by microbiological techniques.

4.6 Fertility, pregnancy and lactation

Pregnancy

This medicine should not be used to treat megaloblastic anaemia of pregnancy because this is due to folate deficiency.

4.7 Effects on ability to drive and use machines

None

4.8 Undesirable effects

Sensitisation to this medicine is rare, but may present as an itching exanthema, and exceptionally as anaphylactic shock.

Acneform and bullous eruptions have been reported rarely.

Patients who have become sensitised to this medicine by injection are often able to tolerate the oral route without trouble.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Overdosage is unlikely to require treatment.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antianemic preparations, Vitamin B12 (cyanocobalamin).

ATC code: B03BA01

This medicine contain cyanocobalamin vitamin B 12, which is used for the treatment of pernicious anaemia, and nutritional deficiencies of vitamin B 12 which results in macrocytic anaemia.

5.2 Pharmacokinetic properties

Absorption:

The absorption of cobalamins from the gut is dependent upon the glycoprotein intrinsic factor.

Distribution:

Cobalamins are transported rapidly into the blood bound to protein, known as transcobalamins.

Elimination:

Cobalamins are stored in the liver and excreted in the bile. They are known to cross the placenta.

5.3 Preclinical safety data

No further relevant data

6. Pharmaceutical particulars
6.1 List of excipients

Lactose monohydrate

Microcrystalline cellulose (pH101)

Croscarmellose sodium

Magnesium stearate

Readymade coating material pink:

Hypromellose HPMC 2910 (E464)

Titanium dioxide (E171)

Macrogol/polyethylene glycol

Carmine (E120)

Black iron oxide (E172)

6.2 Incompatibilities

Not Applicable

6.3 Shelf life

Unopened bottle packs with silica gel: 24 months

Unopened bottle packs: 18 months

Opened bottles: After first opening use within 100 days

6.4 Special precautions for storage

Bottle packs: Store below 25°C. Store in the original package in order to protect from moisture. Keep the bottle container tightly closed.

6.5 Nature and contents of container

HDPE containers with a polypropylene cap containing 50 tablets. Each container contains a silica gel desiccant pouch, which must be kept in the container to help protect your tablets, and it should not be swallowed

HDPE containers with a polypropylene cap containing 50 and 100 tablets

Not all pack sizes may be marketed

6.6 Special precautions for disposal and other handling

No special requirements.

7. Marketing authorisation holder

Glenmark Pharmaceuticals Europe Limited

Laxmi House, 2-B Draycott Avenue

Kenton, Middlesex, HA3 0BU

United Kingdom

8. Marketing authorisation number(s)

PL 25258/0369

9. Date of first authorisation/renewal of the authorisation

15/12/2022

10. Date of revision of the text

18/10/2023

Glenmark Pharmaceuticals Europe Ltd
Company image
Address
Building 2, Croxley Park, Watford, WD18 8YA
Telephone
+44 (0)1923 202 950
Fax
+44 (0)1923 251137
Medical Information Direct Line
0800 458 0383
Stock Availability
+44 (0)1923 202 950